Copyright
©The Author(s) 2017.
World J Hepatol. Jun 28, 2017; 9(18): 797-807
Published online Jun 28, 2017. doi: 10.4254/wjh.v9.i18.797
Published online Jun 28, 2017. doi: 10.4254/wjh.v9.i18.797
Authors | n | Phase | Treatment | Primary end-point |
Keynote-224 | 100 | II | Pembrolizumab | RR |
ongoing | II | Pembrolizumab | DCR | |
CheckMate-040 | I/II | Nivolumab | Safety | |
CheckMate-459 | 726 | III | Nivolumab vs Sorafenib | OS |
TTP |
- Citation: Cidon EU. Systemic treatment of hepatocellular carcinoma: Past, present and future. World J Hepatol 2017; 9(18): 797-807
- URL: https://www.wjgnet.com/1948-5182/full/v9/i18/797.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i18.797